Previous 10 | Next 10 |
The following slide deck was published by Simulations Plus, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Simulations Plus, Inc. 2020 Q4 - Results - Earnings Call Presentation
Simulations Plus, Inc. (SLP) Q4 2020 Earnings Conference Call November 16, 2020 4:15 PM ET Company Participants Cameron Donahue – Hayden Investor Relations Shawn O’Connor – Chief Executive Officer John Kneisel – Chief Financial Officer Conference Call Participants ...
Image source: The Motley Fool. Simulations Plus Inc (NASDAQ: SLP) Q4 2020 Earnings Call Nov 16, 2020 , 4:15 p.m. ET Cameron Donahue -- Partner and Regional Vice President Continue reading For further details see: Simulations Plus Inc ...
Simulations Plus (SLP): FQ4 GAAP EPS of $0.11 beats by $0.03.Revenue of $9.54M (+19.0% Y/Y) beats by $0.16M."Simulations Plus achieved its goal of accelerating organic growth to 15-20%, overcoming headwinds from the COVID-19 pandemic due to continued strong growth from both our software and c...
Full-Year Revenue Increased 22.4% to $41.6 Million; Fourth Quarter Revenue Increased 18.9% to $9.5 Million; Fourth Quarter Diluted EPS of $0.11 and Full-Year Diluted EPS of $0.50 Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling...
Comments Submitted to California’s OEHHA Featured DILIsym Simulations DILIsym Services, Inc. , a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that ...
Conference Call to be on Monday, November 16, 2020, at 4:15 PM ET Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2020, ended August 31, 2020, after the close of the financial ma...
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be participating in the Credit Suisse 29 th Annu...
Latest release includes enhanced Simulx module, a powerful simulator for clinical trial pharmacometrics Lixoft , a Simulations Plus company (Nasdaq: SLP), a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, today anno...
FDA Review Cites DILIsym Results as Part of Turalio ® Submission DILIsym Services, Inc. , a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that sim...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...